tyrosine kinase with immunoglobulin like and EGF like domains 1Genealiases: JTK14 · LMPHM11 · TIE
Q-omics provides the consensus-scored TIE1 profile across patient tissues and cancer cell-line models. TIE1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TIE1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, TIE1 RNA expression shows 21,825 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where TIE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIE1 survival associations across molecular data types. TIE1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIE1 RNA expression–survival associations across cancer types. High TIE1 expression shows unfavorable associations in KIRP, MESO, UVM, BLCA and LUSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TIE1 RNA expression.
This table summarizes TIE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TIE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIE1 shows lower tumor expression in LUAD, KIRP, KICH, LUSC and UCEC and higher tumor expression in HNSC. The LUAD box plot shows higher TIE1 RNA expression in normal versus tumor tissue (log2 FC = −1.848, t-test p < 0.001).
This table shows molecular features associated with TIE1 in patient tissues and cancer cell lines. In patient samples, TIE1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
